US EditionFirst GLP1 in a pill to reduce cardiovascular events in people with type 2 diabetes
Summary by Dr Sue
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
First GLP1 in a pill to reduce cardiovascular events in people with type 2 diabetes
Prefer to listen? Check out my podcast here! We know that several GLP1 receptor agonists reduce cardiovascular events in people with type 2 diabetes – this includes injectables dulaglutide (Trulicity), liraglutide (Victoza), and semaglutide (Ozempic). Semaglutide is also available in an oral (pill) form for type 2 diabetes, called Rybelsus. In 2019, we published the PIONEER 6 study (disclosure: I was an author), which demonstrated cardiovascular…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
